ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVOB Novo-N.Dkk1'b'

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type Share ISIN Share Description
Novo-N.Dkk1'b' LSE:NVOB London Ordinary Share DK0060102614 DKK1 SER'B'
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Transaction in Own Shares

22/12/2008 1:23pm

UK Regulatory


    Transaction in Own Shares
             
Novo Nordisk A/S - Share repurchase programme


On 15 August 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 1.7 billion in the period from 15 August 2008 to
19 December 2008. The programme thereby ended on 19 December 2008.

Since the announcement as of 15 December 2008, the following
transactions have been made under the programme:


                  Number of    Average      Transaction
                   shares   purchase price  value, DKK
Accumulated, last
announcement      5,399,000                1,542,096,704
15 December 2008    110,000    283.2200       31,154,200
16 December 2008    120,000    278.9400       33,472,800
17 December 2008    115,000    278.1100       31,982,650
18 December 2008    110,000    277.7700       30,554,700
19 December 2008    108,500    282.9700       30,702,245
Accumulated under
the programme     5,962,500                1,699,963,299


With the transactions stated above, Novo Nordisk owns a total of
25,721,095 treasury shares, corresponding to 4.1% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Further information:

Media:                 Investors:

Elin K Hansen          Mads Veggerby Lausten
Tel: (+45) 4442 3450   Tel: (+45) 4443 7919
ekh@novonordisk.com    mlau@novonordisk.com

                       Hans Rommer
In North America:      Tel: (+45) 4442 4765
Sean Clements          hrmm@novonordisk.com
Tel: (+1) 609 514 8316
secl@novonordisk.com   Kasper Roseeuw Poulsen
                       Tel: (+45) 4442 4471
                       krop@novonordisk.com


Company Announcement no 82 / 2008

http://hugin.info/2013/R/1279217/285573.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.



1 Year Novo-N.Dkk1'b' Chart

1 Year Novo-N.Dkk1'b' Chart

1 Month Novo-N.Dkk1'b' Chart

1 Month Novo-N.Dkk1'b' Chart

Your Recent History

Delayed Upgrade Clock